一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression.
IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
鉴于当前疗法的长期无效和晚期诊断,肺癌是恶性疾病的主要原因。肿瘤进展受癌细胞与肿瘤微环境(TME)相互作用的影响。据报道,胰岛素样生长因子1受体(IGF1R)影响TME;然而,IGF1R在肺TME中的作用尚未被研究。首先,我们评估了NSCLC患者组织样本中IGF1R的基因组改变和表达,以及IGF1R的血清水平。接下来,我们使用黑色素瘤和Lewis肺癌(LLC)细胞在IGF1R缺陷小鼠中进行了肿瘤异位移植和肺转移。
在此我们报告,NSCLC患者肿瘤样本中IGF1R的扩增和mRNA表达增加,以及蛋白质表达(IGF1R/p-IGF1R)增加,血清中IGF1R水平升高。
此外,小鼠中IGF1R缺陷减少了肿瘤异位移植后的肿瘤生长、增殖、炎症和血管化,并增加了凋亡。在诱导肺转移后,IGF1R缺陷的肺也显示出肿瘤负荷减少,以及肿瘤进展标志物p-IGF1R和p-ERK1/2表达降低。
此外,IGF1R缺陷的肺显示出凋亡增加和增殖、血管化、EMT和纤维化减少,同时炎症和免疫抑制减弱。相应地,IGF1R缺陷降低了血管、成纤维细胞、肿瘤相关巨噬细胞和FOXP3+TIL(肿瘤浸润淋巴细胞)中p-IGF1R的表达。
我们的结果表明,IGF1R促进肺TME中的转移性肿瘤起始和进展。此外,我们的研究表明,IGF1R可能是NSCLC患者药物反应和临床演变早期预测的潜在生物标志物。
Given the long-term ineffectiveness of current therapies and late-stage diagnoses, lung cancer is a leading cause of malignant diseases. Tumor progression is influenced by cancer cell interactions with the tumor microenvironment (TME). Insulin-like growth factor 1 receptor (IGF1R) was reported to affect the TME; however, the role of IGF1R in lung TME has not been investigated.
First, we assessed IGF1R genomic alterations and expression in NSCLC patient tissue samples, as well as IGF1R serum levels. Next, we performed tumor heterotopic transplantation and pulmonary metastases in IGF1R-deficient mice using melanoma and Lewis lung carcinoma (LLC) cells.
Herein we report increased amplification and mRNA expression, as well as increased protein expression (IGF1R/p-IGF1R) and IGF1R levels in tumor samples and serum from NSCLC patients, respectively.
Moreover, IGF1R deficiency in mice reduced tumor growth, proliferation, inflammation and vascularization, and increased apoptosis after tumor heterotopic transplantation. Following induction of lung metastasis, IGF1R-deficient lungs also demonstrated a reduced tumor burden, and decreased expression of tumor progression markers, p-IGF1R and p-ERK1/2.
Additionally, IGF1R-deficient lungs showed increased apoptosis and diminished proliferation, vascularization, EMT and fibrosis, along with attenuated inflammation and immunosuppression. Accordingly, IGF1R deficiency decreased expression of p-IGF1R in blood vessels, fibroblasts, tumor-associated macrophages and FOXP3 + tumor-infiltrating lymphocytes.
Our results demonstrate that IGF1R promotes metastatic tumor initiation and progression in lung TME.
Furthermore, our research indicates that IGF1R could be a potential biomarker for early prediction of drug response and clinical evolution in NSCLC patients.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。